Novel Imaging Analysis of the Marrow Compartment after Myeloablative HSCT Reveals the Kinetics and Degree of Myeloablation and Cell Recovery  by Chakrabarty, Jennifer Holter et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S319University, Cleveland, OH; 3 Cleveland Clinic Foundation,
Cleveland, OH; 4University Hospitals Seidman Cancer Center,
Cleveland, OH; 5University Hospitals Seidman Cancer Center and
Case Western Reserve University, Cleveland, OH; 6Adult Stem Cell
Transplant Program, University of Miami, Sylvester
Comprehensive Cancer Center, Miami, FL
Disease relapse is a major cause of treatment failure
following alloSCT for acute myeloid leukemia (AML). Azaci-
tidine has shown efﬁcacy in treating, and preventing, post-
transplant relapse in patients with AML. Post-SCT azacitidine
administration is challenging due to the possibility of mye-
losuppression and an incomplete understanding of the
optimal dose and schedule. DNMT1 is responsible for
genome methylation in S phase and degraded after bonding
irreversibly to substituted DNA. Hence, the DNMT1 level may
be an attractive pharmacodynamic (PD) endpoint for azaci-
tidine therapy.
We developed a novel DNMT1 assay by ﬂow cytometry as a
PD endpoint for hypomethylating agent therapy. To validate
the assay, HCT116-wild type (WT) and DNMT1-double-
knockout (DKO) cells were incubatedwith 0.5 mMdecitabine,
and were harvested, ﬁxed, and processed for ﬂow cytometry
using DNMT1 antibody in an indirect assay and co-stained
with DAPI to measure DNA content. We assessed the time-
dependent depletion of DNMT1 with decitabine incubation
(Fig. A).
We subsequently assessed DNMT1 in ﬁxed peripheral
blood leukocytes using the same method in 4 AML patients
treated with post-alloSCT azacitidine; either parenterally for
post-SCT relapse (n¼2) or after oral azacitidine maintenance
on clinical protocol NCT 01835587 (n¼2). Peripheral blood
samples were drawn before and 2-6 weeks after starting
azacitidine. Immature myeloblasts were identiﬁed by co-
staining for CD34 and CD117.
We demonstrated depletion in DNMT1 in S-phase
CD34+CD117+ cells after azacitidine in the 4 studied paired
samples. The degree of depletionwas more pronounced with
parenteral versus oral azacitidine. In one patient who
responded favorably to azacitidine, depletion of DNMT1
correlated with reduction in peripheral blood blasts
(CD34+117+ cells) as shown below (Fig. B).
These preliminary data suggest that the DNMT1 assay is a
robust single cell approach to assess PD of hypomethylating
agents. After further validation, this DNMT1 assay may be a
valuable tool to optimize the dose and schedule, and hence
the safety and efﬁcacy of post-alloSCT hypomethylating
therapies.Figure 1. FLT image reconstruction axial spine462
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There are no tests that diagnose graft failure early after he-
matopoietic stem cell transplantation (HSCT); currently, bi-
opsies of single sites are used, thereby limited by small
volume of HSCs. To enhance evaluation of the entire marrow
space, we have developed a new methodology using an
imaging probe, 3’-deoxy-3 18F-ﬂuorothymidine (18FLT) PET/
CT. Previously, by drawing regions of interest on 18FLT PET-
CTs, uptake correlated with rate of engraftment after HSCT.
This approach is limited by subjective choice of regions
within bones. To enhance objectivity and sensitivity, we
developed a computer-based algorithm to isolate the entire
medullary space and determine standard uptake value
(SUV). This method was applied to images from 17 patients
Figure 2. FLT medullary uptake during myeloablation and marrow
repopulation
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myeloablative HSCT for leukemia. Images analyzed included:
1) after ablation (day-1) evaluating for residual hematopoi-
esis, 2) early engraftment after HSCT (day +5-12), and 3) 28
days after HSCT, full marrow reconstitution. The algorithm
sensitively excluded uptake from non-marrow sources by
means of a CT mask that identiﬁed bone structures and
measured the total functional volume within the axial skel-
eton (Figure 1). Spinal and pelvic medullary volumes from CT
mask were median of 586.6 mL (range 400.9- 808.2 mL) and
a median of 860.2 mL (range 592.8-1054.1ml) respectively.
As expected, CT generated volume correlated signiﬁcantly
with height (cm) in spine (p¼.0002, R2¼0.62) and pelvis
(p¼.0125, R2¼0.37), and ideal body weight (kg) in spine
(p<.0001, R2¼0.74) and pelvis (p¼.0012, R2¼0.54). SUV
ranged from 0.6 to 4; marrowactivity was deﬁned> than 1.2,
per published literature. All patients were neutropenic
following HSCT, engrafted in the expected time frame, and
showed full donor chimerism. After myeloablation in the 14
non-relapse patients, less than 2% of the axial skeleton
demonstrated activity (range <1%-13%). By day 5-6 after
HSCT, this increased 8-fold to 17%(range 1%-28%), and it
increased by 36-fold by day 9-12 to 72%(range 56%-89%).
After 28 days, repopulated marrow showed proliferative
activity of 96% (81-99%) (p<0.02 between all 4 time points).
In summary, using a semi-automated analysis of 18FLT up-
take, we show that hematopoiesis of entire axial skeleton
with a single image, which also correlates with height and
ideal body weight, suggesting that this is an accurate and
sensitive assessment of the medullary space. Further, we
show that imaging may assess the degree of myeloablation
after HSCT, and that SUV can describe the degree of marrow
engraftment. Our data show that 18FLT could reveal failure of
myeloablation and engraftment failure within 5-6 days of
HSCT, which could be used to direct novel therapies and
improve outcomes.463
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The beneﬁcial application of regulatory T cells (Treg:
CD4+CD25+FoxP3+) for suppression of GVHD following allo-
geneic HSCTcontinues to evolve. Because of the challenges to
expand large numbers of these cells ex-vivo prior to trans-
plant, strategies to manipulate the compartment in situ
would represent a signiﬁcant advance for therapeutic
application in patients. Several cell surface molecules have
been identiﬁed as targets for expanding Treg cells in vivo.
Here we describe a new approach to regulate GVHD by
manipulating Tregs ﬁrst in the donor and subsequently in
recipients post-HSCT via targeting two signaling pathways,
IL2-CD25 and TL1A-TNFRSF25.
First, we compared different protocols involving simul-
taneous and non-overlapping schedules by infusing IL-2
either free or complexed with anti-JES6mAb (IAC) and a
TL1A-Ig fusion protein (FP) into normal B6-FoxP3RFP mice.
A highly reproducible protocol was developed, wherein FP
was administered ﬁrst, followed by IAC. This routinely
resulted in w50% FoxP3+/CD4+ T cells, and also an overall
increase in the CD4/CD8 ratio in these animals versus
controls (3.7 vs. 1.5 in lymph node and 4.1 vs. 1.7 in splenic
T cells). Notably, expanded Tregs exhibited elevated CD25
expression and there was a 4-5x increase in the KLRG1+
fraction of FoxP3+CD4+ T cells. The expanded Treg popula-
tion in these mice diminished by 50% in the ﬁrst 4 days
following cessation of treatment and returned to normal
levels within 2 weeks. We then examined transplant
outcome after obtaining cells from these Treg expanded
mice as donors for an allogeneic, complete MHC-mis-
matched HSCT. Lymph node cells from Treg-expanded B6-
FoxP3RFP (H2b) mice were transplanted together with
normal TCD-BM into lethally conditioned BALB/c (H2d)
recipients. Recipients were treated with different regimens
of TL1A-Ig and/or free IL-2 (10,000 units/mouse) early
post-HSCT. Mice were monitored for weight change, clin-
ical score and survival. Treg frequencies were determined
in the blood and tissues 1 week post-HSCT. Initial TL1A-Ig
treatment of recipients following transplant with Treg
expanded donor T cells resulted in rapid lethality. These
observations were consistent with the known effector cell
co-stimulation via TNFRSF25 in the presence of antigen.
Only Treg expansion in the donor combined with initial IL-
2 followed by TL1A-Ig treatment of the recipient post-HSCT
resulted in amelioration of GVHD. In summary, a combi-
nation strategy employing the targeted signaling of CD25
and TNFRSF25 was identiﬁed which can markedly expand
Treg cells including a KLRG1+ population. Signaling via
TNFRSF25 followed by CD25 in T cell donors in conjunction
with the reverse targeting of these receptors in recipients
post-transplant resulted in attenuation of GVHD.464
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